Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    163
    ...
ATC Name B/G Ingredients Dosage Form Price
C07AB07 PRESCOR 5 G Bisoprolol - 5mg 5mg Tablet, film coated 345,560 L.L
C09DA04 CO APROVEL B Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 658,483 L.L
N02BE01 EFFERALGAN B Paracetamol - 1g 1g Tablet, film coated 129,009 L.L
C07AB07 ZIOPROL G Bisoprolol - 5mg 5mg Tablet, film coated 409,552 L.L
C09DA04 CO APROVEL B Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 658,483 L.L
M01AH05 ARCOXIA B Etoricoxib - 60mg 60mg Tablet, film coated 1,685,178 L.L
A10BA02 DIANORM 850 G Metformin HCl - 850mg 850mg Tablet, film coated 221,286 L.L
C07AB07 CONCOR B Bisoprolol fumarate - 10mg 10mg Tablet, film coated 1,176,665 L.L
C09DA04 ANDARAN PLUS G Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 598,051 L.L
C10BA04 CHOLIB B Fenofibrate - 145mg, Simvastatin - 20mg Tablet, film coated 1,251,117 L.L
M01AH05 ARTRIX 60 G Etoricoxib - 60mg 60mg Tablet, film coated 1,054,596 L.L
A10BA02 DIANORM 850 G Metformin HCl - 850mg 850mg Tablet, film coated 221,286 L.L
C07AB07 B-COR 10 G Bisoprolol fumarate - 10mg 10mg Tablet, film coated 595,322 L.L
C09DA04 CONVERIUM PLUS G Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 395,090 L.L
C10BA04 CHOLIB B Fenofibrate - 145mg, Simvastatin - 40mg Tablet, film coated 1,358,625 L.L
L04AA37 OLUMIANT B Baricitinib - 2mg 2mg Tablet, film coated 68,053,864 L.L
M01AH05 CONSORT G Etoricoxib - 60mg 60mg Tablet, film coated 338,648 L.L
A03AA04 BEVACOL 135 G Mebeverine HCl - 135mg 135mg Tablet, film coated 532,162 L.L
A10BA02 DIAPHAGE G Metformin HCl - 850mg 850mg Tablet, film coated 147,823 L.L
C09DA04 GIZLAN-PLUS G Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 395,090 L.L
C10BA05 ATOZET B Atorvastatin - 10mg, Ezetimibe - 10mg Tablet, film coated 1,624,706 L.L
L04AA37 OLUMIANT B Baricitinib - 4mg 4mg Tablet, film coated 68,053,864 L.L
M01AH05 COXIFLAM G Etoricoxib - 60mg 60mg Tablet, film coated 1,109,630 L.L
C07AB07 BISOCOR 10 G Bisoprolol fumarate - 10mg 10mg Tablet, film coated 460,746 L.L
C09DA04 IBECARD PLUS 150/12.5 G Irbesartan - 150mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 559,294 L.L
C10BA05 ATOZET B Atorvastatin - 10mg, Ezetimibe - 10mg Tablet, film coated 1,624,706 L.L
L04AA42 MAYZENT B Siponimod - 0.25mg 0.25mg Tablet, film coated 15,102,158 L.L
M01AH05 ETOXA G Etoricoxib - 60mg 60mg Tablet, film coated 1,109,630 L.L
A03AB06 SPASMOMEN B Otilonium bromide - 40mg 40mg Tablet, film coated 438,093 L.L
A10BA02 GLUFORIN 850 G Metformin HCl - 850mg 850mg Tablet, film coated 316,123 L.L
    ...
    163
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025